{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:04:37Z","timestamp":1791821077807,"version":"4.3.4"},"reference-count":41,"publisher":"The Company of Biologists","issue":"5","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI17\/00310, PI17\/00754, PI18\/00974, AC18\/00033"],"award-info":[{"award-number":["PI17\/00310, PI17\/00754, PI18\/00974, AC18\/00033"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"crossref","award":["PI17\/00310, PI17\/00754, PI18\/00974, AC18\/00033"],"award-info":[{"award-number":["PI17\/00310, PI17\/00754, PI18\/00974, AC18\/00033"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"crossref","award":["PI17\/00310, PI17\/00754, PI18\/00974, AC18\/00033"],"award-info":[{"award-number":["PI17\/00310, PI17\/00754, PI18\/00974, AC18\/00033"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>In non-alcoholic steatohepatitis (NASH), decreased nitric oxide and increased endothelin-1 (ET-1, also known as EDN1) released by sinusoidal endothelial cells (LSEC) induce hepatic stellate cell (HSC) contraction and contribute to portal hypertension (PH). Statins improve LSEC function, and ambrisentan is a selective endothelin-receptor-A antagonist. We aimed to analyse the combined effects of atorvastatin and ambrisentan on liver histopathology and hemodynamics, together with assessing the underlying mechanism in a rat NASH model. Diet-induced NASH rats were treated with atorvastatin (10\u2005mg\/kg\/day), ambrisentan (30\u2005mg\/kg\/day or 2\u2005mg\/kg\/day) or a combination of both for 2\u2005weeks. Hemodynamic parameters were registered and liver histology and serum biochemical determinations analysed. Expression of proteins were studied by immunoblotting. Conditioned media experiments were performed with LSEC. HSCs were characterized by RT-PCR, and a collagen lattice contraction assay was performed. Atorvastatin and ambrisentan act synergistically in combination to completely normalize liver hemodynamics and reverse histological NASH by 75%. Atorvastatin reversed the sinusoidal contractile phenotype, thus improving endothelial function, whereas ambrisentan prevented the contractile response in HSCs by blocking ET-1 response. Additionally, ambrisentan also increased eNOS (also known as Nos3) phosphorylation levels in LSEC, via facilitating the stimulation of endothelin-receptor-B in these cells. Furthermore, the serum alanine aminotransferase of the combined treatment group decreased to normal levels, and this group exhibited a restoration of the HSC quiescent phenotype. The combination of atorvastatin and ambrisentan remarkably improves liver histology and PH in a diet-induced NASH model. By recovering LSEC function, together with inhibiting the activation and contraction of HSC, this combined treatment may be an effective treatment for NASH patients.<\/jats:p>","DOI":"10.1242\/dmm.048884","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T06:42:25Z","timestamp":1619246545000},"source":"Crossref","is-referenced-by-count":31,"title":["Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH"],"prefix":"10.1242","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5889-9125","authenticated-orcid":false,"given":"Miren","family":"Bravo","sequence":"first","affiliation":[{"name":"Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Aut\u00f2noma de Barcelona, Barcelona 08035, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imma","family":"Raurell","sequence":"additional","affiliation":[{"name":"Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Aut\u00f2noma de Barcelona, Barcelona 08035, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid 28029, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Barber\u00e1","sequence":"additional","affiliation":[{"name":"Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Aut\u00f2noma de Barcelona, Barcelona 08035, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Hide","sequence":"additional","affiliation":[{"name":"Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Aut\u00f2noma de Barcelona, Barcelona 08035, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid 28029, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Gil","sequence":"additional","affiliation":[{"name":"Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Aut\u00f2noma de Barcelona, Barcelona 08035, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Estrella","sequence":"additional","affiliation":[{"name":"Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Aut\u00f2noma de Barcelona, Barcelona 08035, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Salcedo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3515-9033","authenticated-orcid":false,"given":"Salvador","family":"Augustin","sequence":"additional","affiliation":[{"name":"Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Aut\u00f2noma de Barcelona, Barcelona 08035, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid 28029, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Genesc\u00e0","sequence":"additional","affiliation":[{"name":"Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Aut\u00f2noma de Barcelona, Barcelona 08035, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid 28029, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0935-0029","authenticated-orcid":false,"given":"Mar\u00eda","family":"Martell","sequence":"additional","affiliation":[{"name":"Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Aut\u00f2noma de Barcelona, Barcelona 08035, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid 28029, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"237","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"2021052013233523600_DMM048884C1","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","article-title":"Cirrhosis as new indication for statins","volume":"69","author":"Bosch","year":"2020","journal-title":"Gut"},{"key":"2021052013233523600_DMM048884C2","doi-asserted-by":"publisher","first-page":"20183","DOI":"10.1038\/s41598-019-56366-2","article-title":"Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH","volume":"9","author":"Bravo","year":"2019","journal-title":"Sci. Rep."},{"key":"2021052013233523600_DMM048884C3","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1139\/Y10-038","article-title":"Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats","volume":"88","author":"Cavasin","year":"2010","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"2021052013233523600_DMM048884C4","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/hep.22351","article-title":"Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence","volume":"48","author":"DeLeve","year":"2008","journal-title":"Hepatology"},{"key":"2021052013233523600_DMM048884C5","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1038\/s41598-020-60709-9","article-title":"Hypoxia sensing by hepatic stellate cells leads to VEGF-dependent angiogenesis and may contribute to accelerated liver regeneration","volume":"10","author":"Dirscherl","year":"2020","journal-title":"Sci. Rep."},{"key":"2021052013233523600_DMM048884C6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"2021052013233523600_DMM048884C7","doi-asserted-by":"publisher","first-page":"G27","DOI":"10.1152\/ajpgi.90405.2008","article-title":"Endothelin antagonism in portal hypertensive mice: Implications for endothelin receptor-specific signaling in liver disease","volume":"297","author":"Feng","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2021052013233523600_DMM048884C8","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1097\/MEG.0b013e32833f14a1","article-title":"Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis","volume":"22","author":"Francque","year":"2010","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"2021052013233523600_DMM048884C9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol. Rev."},{"key":"2021052013233523600_DMM048884C10","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"key":"2021052013233523600_DMM048884C11","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/hep.29646","article-title":"Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis","volume":"67","author":"Garc\u00eda-Lezana","year":"2018","journal-title":"Hepatology"},{"key":"2021052013233523600_DMM048884C12","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jhep.2012.03.007","article-title":"Functional aspects on the pathophysiology of portal hypertension in cirrhosis","volume":"57","author":"Garc\u00eda-Pag\u00e1n","year":"2012","journal-title":"J. Hepatol."},{"key":"2021052013233523600_DMM048884C13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1183\/09031936.00138706","article-title":"Results of European post-marketing surveillance of bosentan in pulmonary hypertension","volume":"30","author":"Humbert","year":"2007","journal-title":"Eur. Respir. J."},{"key":"2021052013233523600_DMM048884C14","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1432-1033.1993.tb17824.x","article-title":"The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances: possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus","volume":"213","author":"Kawada","year":"1993","journal-title":"Eur. J. Biochem."},{"key":"2021052013233523600_DMM048884C15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1124\/jpet.114.220491","article-title":"Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists","volume":"352","author":"Kenna","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021052013233523600_DMM048884C16","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"2021052013233523600_DMM048884C17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1476-5926-5-5","article-title":"Endothelin-1 enhances fibrogenic gene expression, but does not promote DNA synthesis or apoptosis in hepatic stellate cells","volume":"5","author":"Koda","year":"2006","journal-title":"Comp. Hepatol."},{"key":"2021052013233523600_DMM048884C18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0168-8278(00)80188-9","article-title":"Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance","volume":"32","author":"Kojima","year":"2000","journal-title":"J. Hepatol."},{"key":"2021052013233523600_DMM048884C19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cld.2017.08.003","article-title":"The natural history of nonalcoholic fatty liver disease\u2014an evolving view","volume":"22","author":"Lindenmeyer","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"2021052013233523600_DMM048884C20","doi-asserted-by":"publisher","first-page":"49929","DOI":"10.1074\/jbc.M306930200","article-title":"Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein betagamma subunit signaling to protein jinase B\/Akt","volume":"278","author":"Liu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2021052013233523600_DMM048884C21","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1172\/JCI119103","article-title":"Growth inhibitory properties of endothelin-1 in activated human hepatic stellate cells: a cyclic adenosine monophosphate-mediated pathway: Inhibition of both extracellular signal-regulated kinase and c-Jun kinase and upregulation of endothelin B receptors","volume":"98","author":"Mallat","year":"1996","journal-title":"J. Clin. Invest."},{"key":"2021052013233523600_DMM048884C22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","article-title":"The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins","volume":"58","author":"Marrone","year":"2013","journal-title":"J. Hepatol."},{"key":"2021052013233523600_DMM048884C23","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: Behind the molecular mechanisms of statins","volume":"64","author":"Marrone","year":"2015","journal-title":"Gut"},{"key":"2021052013233523600_DMM048884C24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1378\/chest.08-1028","article-title":"Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities","volume":"135","author":"McGoon","year":"2009","journal-title":"Chest"},{"key":"2021052013233523600_DMM048884C25","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.cgh.2012.05.008","article-title":"Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease","volume":"10","author":"Mendes","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"2021052013233523600_DMM048884C26","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jhep.2011.01.053","article-title":"Insulin resistance and liver microcirculation in a rat model of early NAFLD","volume":"55","author":"Pasar\u00edn","year":"2011","journal-title":"J. Hepatol."},{"key":"2021052013233523600_DMM048884C27","doi-asserted-by":"publisher","first-page":"e32785","DOI":"10.1371\/journal.pone.0032785","article-title":"Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD","volume":"7","author":"Pasar\u00edn","year":"2012","journal-title":"PLoS ONE"},{"key":"2021052013233523600_DMM048884C28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1517\/13543780802680186","article-title":"Endothelin receptor antagonism in portal hypertension","volume":"18","author":"Pitts","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2021052013233523600_DMM048884C29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins: Old drugs as new therapy for liver diseases?","volume":"70","author":"Pose","year":"2019","journal-title":"J. Hepatol."},{"key":"2021052013233523600_DMM048884C30","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S0270-9139(02)00092-7","article-title":"Regulation of endothelin-A receptor sensitivity by cyclic adenosine monophosphate in rat hepatic stellate cells","volume":"36","author":"Reinehr","year":"2002","journal-title":"Hepatology"},{"key":"2021052013233523600_DMM048884C31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hep.510240137","article-title":"Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance","volume":"24","author":"Rockey","year":"1996","journal-title":"Hepatology"},{"key":"2021052013233523600_DMM048884C32","first-page":"193","article-title":"Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture","volume":"24","author":"Rockey","year":"1992","journal-title":"J. Submicrosc. Cytol. Pathol."},{"key":"2021052013233523600_DMM048884C33","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1172\/JCI116769","article-title":"Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo","volume":"92","author":"Rockey","year":"1993","journal-title":"J. Clin. Invest."},{"key":"2021052013233523600_DMM048884C34","doi-asserted-by":"publisher","first-page":"40461","DOI":"10.1038\/srep40461","article-title":"A nitric oxide-donating statin decreases portal pressure with a better toxicity profile than conventional statins in cirrhotic rats","volume":"7","author":"Rodr\u00edguez","year":"2017","journal-title":"Sci. Rep."},{"key":"2021052013233523600_DMM048884C35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.37349\/emed.2020.00011","article-title":"Nonalcoholic fatty liver disease and portal hypertension","volume":"1","author":"Ryou","year":"2020","journal-title":"Explor. Med."},{"key":"2021052013233523600_DMM048884C36","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"2021052013233523600_DMM048884C37","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1136\/gutjnl-2014-308800","article-title":"Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension","volume":"64","author":"Trebicka","year":"2015","journal-title":"Gut"},{"key":"2021052013233523600_DMM048884C38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology"},{"key":"2021052013233523600_DMM048884C39","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1034\/j.1600-0676.2001.021002114.x","article-title":"Enhanced expression of endothelin receptor subtypes in cirrhotic rat liver","volume":"21","author":"Yokomori","year":"2001","journal-title":"Liver"},{"key":"2021052013233523600_DMM048884C40","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease \u2013 A global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"2021052013233523600_DMM048884C41","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1055\/s-0036-1597411","article-title":"Selective endothelin-a-blocker decrease portal pressure in patients with cirrhosis. A feasibility study combining the local intraarterial and systemic administration","volume":"54","author":"Zipprich","year":"2016","journal-title":"Z. Gastroenterol."}],"container-title":["Disease Models &amp; Mechanisms"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.048884\/1826618\/dmm048884.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.048884\/2070856\/dmm048884.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.048884\/2070856\/dmm048884.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T09:23:45Z","timestamp":1621502625000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.biologists.com\/dmm\/article\/14\/5\/dmm048884\/268318\/Synergic-effect-of-atorvastatin-and-ambrisentan-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.1242\/dmm.048884","relation":{},"ISSN":["1754-8403","1754-8411"],"issn-type":[{"value":"1754-8403","type":"print"},{"value":"1754-8411","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]},"article-number":"dmm048884"}}